Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Glioblastoma 52Lung Neoplasms 49Breast Neoplasms 46Prostatic Neoplasms 39Head and Neck Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Esophageal Neoplasms 30Brain Neoplasms 28Lymphoma 27Gliosarcoma 27Rectal Neoplasms 24Hodgkin Disease 24Pancreatic Neoplasms 22Adenocarcinoma Of Esophagus 22Central Nervous System Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Neoplasms 20Lymphoma, Non-Hodgkin 17Leukemia 17Glioma 17Burkitt Lymphoma 16Sarcoma 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Carcinoma, Squamous Cell 14Colorectal Neoplasms 13Astrocytoma 13Neoplasm Metastasis 12Melanoma 12

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × HER2 Positive Esophagogastric Cancer × Radiotherapy × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡